Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Cresco Labs Inc. reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of -66.67% [1] - The company generated revenues of $164.91 million for the quarter ended September 2025, slightly exceeding the Zacks Consensus Estimate by 0.71%, but down from $179.78 million a year ago [2] - The stock has underperformed the market, gaining about 9.5% year-to-date compared to the S&P 500's 14.3% increase [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $163.65 million, and for the current fiscal year, it is -$0.13 on revenues of $657.23 million [7] - The trend of estimate revisions for Cresco Labs Inc. has been unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which Cresco Labs belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting a challenging environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Cresco Labs' stock performance [5]